Legend Biotech
Legend Biotech Corporation, a prominent player in the biotechnology industry, is headquartered in the United States. Founded in 2014, the company has rapidly established itself as a leader in cell therapy, particularly in the development of innovative treatments for cancer. With a focus on CAR-T cell therapies, Legend Biotech's flagship product, cilta-cel, has garnered significant attention for its unique approach to targeting multiple myeloma.
Operating primarily in the US and expanding its reach globally, Legend Biotech has achieved notable milestones, including strategic partnerships and advancements in clinical trials. The company is recognised for its commitment to advancing personalised medicine, positioning itself at the forefront of the biopharmaceutical landscape. With a robust pipeline and a dedication to transformative therapies, Legend Biotech continues to make significant strides in improving patient outcomes.
+19 vs industry average
Legend Biotech’s score of 57 is higher than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Legend Biotech?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2027
Reported emissions
Scope 3 accounts for ••• of total emissions.
Legend Biotech's reported carbon emissions
Legend Biotech, headquartered in the US, reported total Scope 1 and 2 emissions of approximately 12.7 million kg CO2e for the year 2024. For 2023, their Scope 1 and 2 emissions totalled approximately 13 million kg CO2e. The company’s disclosed emissions currently cover Scope 1 and Scope 2. Scope 3 emissions data, specifically for purchased goods and services, is noted as missing. Legend Biotech's climate commitments and reduction targets are cascaded from its parent company, Genscript Biotech Corporation. While specific reduction targets for Legend Biotech are not detailed independently, the company participates in initiatives guided by its ultimate parent organisation. Genscript Biotech Corporation is the source for Legend Biotech's Science Based Targets initiative (SBTi) commitments and their participation in the Race to Zero (RTZ) initiative. Further details on specific reduction goals are inherited through this corporate family relationship.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Legend Biotech’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Legend Biotech yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Inherited from Genscript Biotech Corporation
Carbon Disclosure Project
Inherited from Genscript Biotech Corporation
The Climate Pledge
UN Global Compact Climate Champions initiative
Inherited from Genscript Biotech Corporation
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Legend Biotech
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project